Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Pelosi, Valeria (2008) Ruoli distinti delle due isoforme di recettori degli estrogeni nella disfunzione vascolare in modelli animali di diabete. [Tesi di dottorato]

Full text disponibile come:

Documento PDF

Abstract (inglese)

Recent large-scale clinical trials found a significantly lower incidence of diabetes in postmenopausal women on hormone replacement therapy despite no improvement in vascular outcomes. The mechanisms accounting for this outcome, however, are largely unknown although estrogen is increasingly
recognized as an important regulator of glucose homeostasis. Because the endogenous hormone binds to its receptors with identical affinity, the metabolic effects of individual estrogen receptor (ER) isoforms, ERa and ERb, are hard to entangle and appear to be tissue- and species-specific. Accordingly, there is little information as to how ERa and ERb affect the course and timeline of diabetic vascular dysfunction, which ultimately results in macrovascular complications of clinical relevance.
We previously demonstrated that estrogen’s anti-inflammatory activity is attenuated in vascular smooth muscle cells (SMCs) from streptozotocin (STZ)- diabetic rats, which display ERb overexpression with respect to normoglycemic controls. The biological significance of ERb overexpression in vascular cells from diabetic rats is as yet unclear. Data from our group indicate that moderately selective ERb agonists induce the expression of inflammatory enzymes in rat vascular SMCs. There is also evidence that ERa mediates protective antiinflammatory effects in vascular and nonvascular tissues including pancreatic b- cells. ERa-selective, but not ERb-selective agonists improve vascular function by mediating vessel relaxation at concentrations where receptor selectivity is
Based on this knowledge, we set out to assess the relative contribution of ER isoforms to the progression of experimental insulin-deficient diabetes and the accompanying vascular dysfunction in rodents through a comprehensive physiological and pharmacological approach using ER-deficient mice, cultured
vascular SMCs and ER-selective agonists.
Primary cultures of vascular smooth muscle cells prepared from control and streptozotocin-injected rats were stimulated with a cytokine mixture comprising TNF-a, interleukin-1b and interferon-g for 24 h in the presence or absence of test compounds, the ER-selective agonists PPT and DPN. The increased expression of inducible NO sythase (iNOS), a classical indicator of vascular inflammation, was significantly reduced in a concentration-dependent manner by the ERa selective agonist PPT, while the ERb selective ligand DPN further enhanced iNOS
To explore potential mechanisms of the distinct iNOS regulation mediated by ERa and ERb and the observed loss of regulation through ERa in SMCs from diabetic rats, we transfected both ER isoforms at increasing plasmide:reporter ratios into SMCs and measured ERE-TATA-luc activity after E2 treatment. ERa
and ERb transcriptional activity in response to 1 nmol/L E2 treatment for 24 h consistently increased in both SMC groups. This suggests that the transcriptional machinery of ER isoforms is maintained in SMCs from diabetic rats.
The opposite regulation of iNOS function by ER-selective agonist in control SMCs could be secondary to differential modulation of nuclear p65 translocation, an important component of E2 anti-inflammatory action. Whereas LPS enhanced the nuclear staining of p65, PPT and DPN blocked this pathway, suggesting that ER-mediated iNOS control in vascular SMCs was independent from the NF-kB system.
Fasting serum glucose levels were higher in ERa -/- compared with ERb -/- or wild-type (wt) mice. Diabetes was induced in 8-week-old mice by a single i.p. injection of STZ (150 mg/Kg). Despite similar worsening of glycaemic control, exposure to STZ caused significantly greater mortality in ER? -/- (41%) than in
ER? -/- (12%) or wt (14%) mice. Vascular biology studies were performed in cultured aortic rings isolated from wt and ER-knockout mice. Aortic rings were stimulated with inflammatory agents in the presence and absence of test
compounds. Treatment of isolated mouse aortic rings with 1 nM 17b-estradiol for 24 h attenuated cytokine-driven formation of inducible NO synthase (iNOS) as detected by Western blotting. This effect was shared by the ERa-selective agonist PPT but not by the ERb-selective agonist DPN. Accordingly, 17b-estradiol reduced iNOS formation in aortic rings from ERb -/- but not ERa -/- mice.
To sum up, combined use of ER-knockout mice and ER-selective agents provided evidence for an anti-inflammatory role for ER? as well as a potential pro-inflammatory role for ER? in the arterial wall. Cellular and animal experiments indicated that ER? and ER? play a relevant role in the control of glucose metabolism, vascular inflammatory responses and diabetes progression in rodents. Based on the present findings, ER?-selective activation may represent a promising pharmacologic approach to the therapeutic modulation of diabetic vascular dysfunction.

Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Dorigo, Paola
Correlatore:Cignarella, Andrea
Dottorato (corsi e scuole):Ciclo 20 > Corsi per il 20simo ciclo > FARMACOLOGIA E TOSSICOLOGIA, TERAPIA RIANIMATIVA E INTENSIVA
Data di deposito della tesi:Gennaio 2008
Anno di Pubblicazione:Gennaio 2008
Parole chiave (italiano / inglese):estrogeni, diabete, iNOS
Settori scientifico-disciplinari MIUR:Area 05 - Scienze biologiche > BIO/14 Farmacologia
Struttura di riferimento:Dipartimenti > pre 2012 - Dipartimento di Farmacologia ed Anestesiologia "E. Meneghetti"
Codice ID:438
Depositato il:10 Set 2008
Simple Metadata
Full Metadata
EndNote Format


I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Akishita M., Ouchi Y. , Miyoshi H. et al. Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 1997; 30: 1-10. Cerca con Google

2. Alipui C., Tenner T. E. Jr., Ramos K. Rabbit aortic smooth muscle cell culture: a model for the pharmacological study of diabetes-induced alterations in cell proliferation. J Pharmacol. Methods 1992; 26: 211-222. Cerca con Google

3. Barchiesi F., Jackson E.K., Imthurn B. et al. Differential regulation of estrogen receptor subtypes ? and ? in human aortic smooth muscle cells by oligonucleotides and estradiol. J Clin Endocrinol Metab 2004 ; 89 : 2373-2381. Cerca con Google

4. Bardell A.L., Macleod K.M. Evidence for inducible nitric-oxide synthase expression and activity in vascular smooth muscle of streptozotocin diabetic rats. J Pharmacol Exp Ther. 2001; 296: 252-259. Cerca con Google

5. Barrett-Connor E. Is insulin-dependent diabetes mellitus caused by coxsackie virus B infection? A review of epidemiologic evidence. Rev Infect Dis 1985; 7:207-215. Cerca con Google

6. Barrett-Connor E. Sex differences in coronary heart disease: why are women so superior? Circulation 1997; 95: 252-264. Cerca con Google

7. Barros RP., Machado UF., Gustafsson J?…. Estrogen receptors: new players in diabetes mellitus Trends Mol Med. 2006;12:425-431. Cerca con Google

8. Barros RP., Machado UF., Warner M., Gustafsson J?…. Muscle GLUT4 regulation byestrogen receptors ER? and ER?. Proc Natl Acad Sci U S A. 2006;103:1605-1608. Cerca con Google

9. Beckman JA., Goldfine AB., Gordon MB. et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001; 103: 1618-1623 Cerca con Google

10. Bhalla RC., Toth KF., Bhatty RA. et al. Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol 1997; 272: H1996-H2003 Cerca con Google

11. Block N., Komori K., Robinson K. et al. Diabetes-associated impairment of hepatic insulin receptor tyrosine kinase activity : a study of mechanisms. Endocrinology 1991; 128: 312-322. Cerca con Google

12. Bolego C, Cignarella A, Sanvito P, Pelosi V, Pellegatta F, Puglisi L, Pinna C. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-? agonists and is abolished by estrogen deprivation. J Pharmacol Exp Ther 2005; 313:1203-1208 Cerca con Google

13. Bolego C., Cignarella A., Ruzza R. et al. Differential effects of low- and high-dose estrogen treatments on vascular responses in female rats. Life Sci 1997; 60: 2291-2302. Cerca con Google

14. Bolego C., Cignarella A., Zancan V. et al. Diabetes abolishes the vascular protective effects of estrogen in female rats. Life Sci 1999; 64: 741-749. Cerca con Google

15. Bomalaski J.S., Chen M.J., Clark M.A. Induction of phospholipase A2 activity and synthesis of phospholipase A2 activating protein (PLAP) by tumor necrosis factor (Abstract). Arthritis Rheum 1987; 30: S28. Cerca con Google

16. Borissova A.M., Zaharieva S., Tankova T.S.V. et al. Prostaglandin E2 affects both insulin secretion and peripheral insulin sensitivity. Diabetes Metab 1991; 17: 346-349. Cerca con Google

17. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321. Cerca con Google

18. Bryzgalova G., Gao H., Ahren B., et al. Evidence that oestrogen receptor-? plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia. 2006;49:588-597. Cerca con Google

19. Brzozowski AM., Pike ACW., Dauter Z. et al. Molecular basis of agonism and antagonist in the estrogen receptor. Nature 1997; 389, 753-758 Cerca con Google

20. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991; 87: 432-438. Cerca con Google

21. Byers MJ, Zangl A, Phernetton TM, Lopez G, Chen DB, Magness RR. Endothelial vasodilator production by ovine uterine and systemic arteries: ovarian steroid and pregnancy control of ERalpha and ERbeta levels. J Physiol 2005;565(Pt 1):85-99 Cerca con Google

22. Cao G., Liang Y., Broderick CL., et al. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem. 2003;278:1131-1136. Cerca con Google

23. Castano E., Vorojekina DP. and Notides AC. Phosphorylation of serine-167 on the human estrogen receptor is important for estrogen response element binding and transcriptional activation Biochem J 1997; 326:149-157 Cerca con Google

24. Cenni B., Picard D. Ligand - independent activation of steroid receptors: new roles for old players. Trends Endocrinol Metab 1999; 10: 41-46. Cerca con Google

25. Chambliss KL., Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002; 23:665-686 Cerca con Google

26. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H. et al. Estrogen receptor beta mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103: 401-406. Cerca con Google

27. Cignarella A., Bolego C., Pinna C. et al. The influence of sex hormones on vascular responses in the aorta of streptozotocin-diabetic male rats. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 514-520. Cerca con Google

28. Cignarella A., Paoletti R., Puglisi L. Direct effects of estrogen on the vessel wall. Med Res Rev 2001; 21: 171-184. Cerca con Google

29. Cosentino F., Eto M., De Paolis P. et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003; 107: 1017-1023 Cerca con Google

30. Cosentino F., Hishikawa K., Katusic ZC. et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997;96: 25-28. Cerca con Google

31. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, Chambon P, Bayard F, Arnal JF. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res. 2002;90(4):413-9. Cerca con Google

32. De Caterina R., Libby P., Peng H.B. et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatiry cytokines. J Clin Invest 1995; 96: 60-68. Cerca con Google

33. De Vera M.E. , Shapiro R.A., Nussler A.K. et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci USA 1996; 93: 1054-1059. Cerca con Google

34. De Vriese AS., Verbeuren TJ., Van de Voorde J., et al. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-974 Cerca con Google

35. Dimitriadis E., Griffin M., Owens D. et al. Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition. Diabetologia 1995; 38:1300-1306. Cerca con Google

36. Dong Z.Y., Qi X.O., Xie K.P. et al. Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages. J Immunol 1993; 151: 2717-2724. Cerca con Google

37. Dubal DB., Zhu H., Yu J. et al. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci USA 2001; 98:1952-1957 Cerca con Google

38. Dubey R.K., Jackson E.K., Gillespie D.G. et al. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler Throomb Vasc Biol 2000; 20: 964-972. Cerca con Google

39. Dubey R.K., Jackson E.K., Lüscher T.F. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin-1 receptors. J Clin Invest 1995; 96: 141-149. Cerca con Google

40. Dubey RK., Oparil S., Imthurn B. et al. Sex hormones and hypertension. Cardiovasc Res 2002; 53:688-708 Cerca con Google

41. Edwards DP Regulation of signal transduction pathways by estrogen and progesterone. Annu. Rev. Physiol. 2005; 67:335-76 Cerca con Google

42. El Tanani M., Hickman S., Thomas C. et al. Two separate mechanisme for ligand-indipendent activation of the estrogen receptor. Mol Endocrinol 1997; 11 : 928-937 Cerca con Google

43. Endoh H., Maruyama K., Masuhiro Y. et al. Purification and identfication of p68 RNA helicase acting as a transcriptional coactivator specific of the activation funcion of Human estrogen receptor ?. Mol Cell Bio 1999; 19: 5363-5372 Cerca con Google

44. Esposito K., Nappo F., Marfella R. et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072 Cerca con Google

45. Förstermann U., Closs E.I., Pollok J.S. et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-1131. Cerca con Google

46. Förstermann U., Kleinert H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 352: 351-364. Cerca con Google

47. Fujii Y., Kaizuka M., Hashida F., et al. Insulin regulates Na+/glucose cotransporter activity in rat small intestine. Biochim Biophys Acta 1991; 1063: 90-94. Cerca con Google

48. Furchgott, RF., Zawadzki JV., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcoline, Nature 1980; 288: 373-376. Cerca con Google

49. Galea E, Santizo R., Feinstein DL. et al. Estrogen inhibits NF-kB dependent inflammation in brain endothelium without interfering with IkB degradation. Neuroreport 2002; 13: 1469-1472 Cerca con Google

50. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibits mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777. Cerca con Google

51. Gaub M.-P., Bellard M., Sheuer I. et al. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 1990; 63: 1267-1276 Cerca con Google

52. Ghisletti S, Meda C, Maggi A, Vegeto E. 17?-estradiol inhibits inflammatory gene expression by controlling NF-kB intracellular localization. Mol Cell Biol. 2005; 25: 2957-68 Cerca con Google

53. Godsland IF. Oestrogens and insulin secretion. Diabetologia. 2005;48:2213-2220. Cerca con Google

54. Greene G.L., Glina P., Waterfield M., et al. Sequence and expression of human estrogen receptor complementary DNA. Science 1986; 231:1150-4 Cerca con Google

55. Gunnett CA., Chu Y., Heistad DD. et al. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am J Physiol. 1998; 275: H416-H421 Cerca con Google

56. Gunnett CA., Heistad DD., Faraci FM. Gene-targeted mice reveal a critical role for inducible nitric oxide synthase in vascular dysfunction during diabetes. Stroke 2003; 34: 2970-2974 Cerca con Google

57. Guo X, Razandi M, Pedram A, Kassab G, Levin ER. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. J Biol Chem 2005;280:19704-10 Cerca con Google

58. Guzik T.J., Korbut T., Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. Physiol Pharmacol 2003; 54: 469-487. Cerca con Google

59. Guzik T.J., West N., Pillai R. et al. Nitric oxide modulates superoxide release and peroxinitrite formation in human blood vessels. Hypertension 2002; 39: 1088-1094. Cerca con Google

60. Hamon M., Vallet B., Bauters C. et al. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994; 90: 1357-1362. Cerca con Google

61. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol. 2003;206(1-2):13-22. Cerca con Google

62. Harrington WR., Sheng S., Barnett DH., et al. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen esponsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol. 2003;206:13-22. Cerca con Google

63. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Endocrinology 2002; 143:4172-4177. Cerca con Google

64. Hayashi T., Fukuto J.M., Ignarro L.J et al. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992; 89: 11259-11263. Cerca con Google

65. Hayashi T., Ishikawa t., Yamada K., et al. Biphasic effect of estrogen on neuronal constitutive nitric oxide synthase via Ca2+-calmodulin dependent mechanism Biochem Biophys Res Commun 1994; 203: 1013-1019 Cerca con Google

66. Hebden R.A., Gardiner S., Bennett T., at al. The influence of streptozotocin-induced diabetes mellitus on fluid and electrolyte handling in rats. Clin Sci 1986; 70: 111-117. Cerca con Google

67. Heyliger C.E. Pierce G.N., Singal P.K. et al. Cardiac alpha-and beta-adrenergic receptor alterations in diabetic cardiomyopathy. Basic Res Cardiol 1982; 77: 610-618. Cerca con Google

68. Hirata K., Kuroda R., Sakoda T. et al. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 1995; 25: 180-185. Cerca con Google

69. Hodgin JB., Krege JK., Redick RL. et al. Estrogen receptor alpha is a major mediator of 17?-estradiol's atheroprotective effects on lesion size in Apo E-/- mice. J Clin Invest 2001; 107:333-340 Cerca con Google

70. Hopfner RL., Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 1999; 42:1383-1394 Cerca con Google

71. Ignar-Trowbridge DM., Pimentel M., Parker MG. et al. Peptide growth factor cros-talk with estrogen receptor requires the A/B domain and occurs independently of proteine kinase C or estradiol. Endocrinology 1996; 137: 1735-1744 Cerca con Google

72. Inoguchi T., Battan R., Handler E. et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in aorta and heart of diabetic rats : Differential reversibility to glycemic control by islet transplantion. Proc Natl Acad Sci USA 1992; 89: 11059- 11063. Cerca con Google

73. Inoguchi T., Li P., Umeda F. et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-1945 Cerca con Google

74. Ischiropoulos H., al-Melhdi A.B. Peroxynitrite-mediated oxidative protein modification. FEBS Lett 1995; 364: 279-282. Cerca con Google

75. Junod A., Lambert A.E., Orci L. et al. Studies of the diabetogenic action of streptozotocin. Pro Soc Exp Biol Med 1967; 126: 201-205. Cerca con Google

76. Kanaya AM., Herrington D., Vittinghoff E. et al. Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study — a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1-9. Cerca con Google

77. Kannel WB., Wilson PW. Risk factor that attenuate the female coronary disease advatage. Arch Intern Med 1995; 155:57-61 Cerca con Google

78. Kansaki T., Shinomiya M., Ueda S. et al Enhanced arterial intimal thickening after balloon catheter injury in diabetic animals accompanied by PDGF--receptor overexpression of aortic media Eur J Clin Inv 1994; 24:377-381 Cerca con Google

79. Kansaki T., Shinomiya M., Ueda S. et al. Enhanced arterial intimal thickening after baloon catheter injury in diabetic animals accompanied by PDGF ?-receptor overexpression of aortic media. Eur J Clin Inv 1994 ;24 :377-381. Cerca con Google

80. Kato S., Endoh H., Masuhiro Y. et al. Activation of the estrogen receptor through phosphoryltion by mitogen-activated protein kinase. Science 1995; 270: 1491-1494 Cerca con Google

81. Kelly MJ., Levin ER. Rapid action of plasma membrane estrogen receptor. Trends Endocrinol Metab 2001; 12: 152-156 Cerca con Google

82. Kelly MJ., Qiu J. and Ronnekleiv OK. Estrogen modulation of G-protein-coupled receptor actiation of potassium channels in the central nervous system. Ann NY Acad Sci 2003; 1007: 6-16 Cerca con Google

83. Kibbe M., Billiar T., Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 1999; 43: 650-657. Cerca con Google

84. Kleinert H., Euchenhofer C., Ihrig-Biedert I. et al. Glucocorticoids inhibit the induction of NO synthase II (iNOS) by downregulating cytokine-induced activity of transcription factor NF- kB. Naunyn-Schmiedeberg's Arch Pharmacol [suppl] 1995; 351: R76. Cerca con Google

85. Korte T., Fuchs M., Arkudas A., et al. Female mice lacking estrogen receptor ? display prolonged ventricular repolarization and reduced ventricular automaticity after myocardial infarction. Circulation. 2005;111:2282-90. Cerca con Google

86. Krasinski K., Spyridopoulos I., Asahara T et al. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997; 95: 1768-1772 Cerca con Google

87. Krolewski A.S., Warram J.H., Valsania P. et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 90 (Suppl 2A) 1991; 56S-61S. Cerca con Google

88. Kunz D., Mü hl H., Walker G. et al. Two distinct signalling pathways trigger the expression of inducible nitric oxide synthase in rat renal mesangial cells. Proc Natl Acad Sci USA 1994; 91: 5387-5391. Cerca con Google

89. Kushner P., Agard DA., Greene GL. Et al Estrogen receptor pathways to AP1. J Steroid Biochem Mol Biol 2000; 74: 311-317 Cerca con Google

90. Laffitte BA., Chao LC., Li J., et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A. 2003;100:5419-5424. Cerca con Google

91. Le May C., Chu K., Hu M. et al. Estrogens protect pancreatic ?-cells from apoptosis and prevent insulindeficient diabetes mellitus in mice. Proc Natl Acad Sci U S A. 2006;103:9232-9237. Cerca con Google

92. Le Mellay V., Grosse B., Lieberherr M., Phospholipase C and membrane action of calcitriol and estradiol J. Biol Chem 1997; 272: 11902-11907 Cerca con Google

93. Lee W.I. et al. Impact of diabetes on coronary artery disease in women and men:a meta analysis of prospective studies. Diabetes Care 2000; 23: 962-8. Cerca con Google

94. Li H., Föstermann U. Nitric oxide in the pathogenesis of vascular disease. Pathol 2000; 190: 244-254 Cerca con Google

95. Li J., McMurray RW. Effects of estrogen receptor subtype-selective agonists on immune functions in ovariectomized mice. Int Immunopharmacol 2006;6:1413-23. Cerca con Google

96. Lowry O.H. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275 Cerca con Google

97. Ma ZQ., Santagati S., Patrone C. et al. Insulin-like grown factors activate estrogen receptor to control the grown and differentiation of the human neuroblastoma cell line SK-ER3. Mol Endocrinol 1994; 8:910-918 Cerca con Google

98. Maggi A., Cignarella A., Brusadelli A. et al. Diabetes undermines estrogen control of inducible nitric oxide synthase function in rat aortic smooth muscle cells through overexpression of estrogen receptor-?. Circulation 2003; 108: 211-217. Cerca con Google

99. Mandup-Poulsen T. Cytokine-mediated beta-cell destruction: the molecular effector mechanism causing IDDM (Abstract). J Autoimmun 1990; 3: 77. Cerca con Google

100. Margolis KL., Bonds DE., Rodabough RJ., et al. Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-1187. Cerca con Google

101. Marletta M.A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994; 78: 927-930. Cerca con Google

102. Marriott LK., McGann-Gramling KR., Hauss-Wegrzyniak B. et al. Brain infusion of lipopolysaccharide increases uterine growth as a function of estrogen replacement regimen: suppression of uterine estrogen receptor-? by constant, but not pulsed, estrogen replacement. Endocrinology. 2007;148:232-240. Cerca con Google

103. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002; 296: 1642-1644. Cerca con Google

104. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811. Cerca con Google

105. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308:1583-1587. Cerca con Google

106. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002; 90:3F-6F. Cerca con Google

107. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012. Cerca con Google

108. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392:49-53 Cerca con Google

109. Nadal A., Ropero AB:, Laribi O. et al. Nongenomic actions of estrogens xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen recptor alpha and estrogen receptor beta Proc Natl Acad Sci USA 2000; 97:11603-11608 Cerca con Google

110. Nakaki T., Nakayama M., Kato R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol 1990; 189: 347-353. Cerca con Google

111. Nakamura Y, Suzuki T, Miki Y, Tazawa C, Senzaki K, Moriya T, Saito H, Ishibashi T, Takahashi S, Yamada S, Sasano H. Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Mol Cell Endocrinol. 2004;219:17-26 Cerca con Google

112. Natan C.F., Hibbs J.B. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 1991; 3: 65-70. Cerca con Google

113. National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057. Cerca con Google

114. Nicosia R.F., Nicoria S.V., Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994; 145: 1023-1029. Cerca con Google

115. Nordmeyer J, Eder S, Mahmoodzadeh S, Martus P, Fielitz J, Bass J, Bethke N, Zurbrugg HR, Pregla R, Hetzer R, Regitz-Zagrosek V. Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation 2004;110:3270-5. Cerca con Google

116. O'Lone R., Knorr K., Jaffe IZ. et al. Estrogen receptors ? and ? mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol Endocrinol. 2007;21:1281-1296. Cerca con Google

117. Oparil S., Levine R.L., Chen S.J. et al. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation 1997; 95: 1301-1307. Cerca con Google

118. Palmer RMJ., Ferrige AG., Moncada S., , Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526. Cerca con Google

119. Patrone C., Ma Z., Pollio G. et al. Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells. Mol Endocrinol 1996; 10: 499-507 Cerca con Google

120. Paul A., Doherty K., Plevin R. Differential regulation by protein kinase C isoforms of nitric oxide synthase induction in RAW 264.7 macrophages and rat aortic smooth muscle cells. Br J Pharmacol 1997; 120: 940-946. Cerca con Google

121. Pelzer T., Jazbutyte V., Hu K. et al The estrogen receptor-α agonist 16-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovascular Res 2005; 67:604-612 Cerca con Google

122. Philips A., Chalbos D., Rochefort H., Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 1993; 268: 14103-14108 Cerca con Google

123. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 1997; 29: 8-15. Cerca con Google

124. Pieper GM., Peltier BA. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995; 25: 397-403 Cerca con Google

125. Pietras R. and Szego CM. Specific binding sites for estrogen at the outer surfaces of isolatd endometrial cells. Nature 1977; 265: 69-72 Cerca con Google

126. Pinna C., Cignarella A., Zanardo R. et al. Gender differences and antioxidant treatment affect aortic reactivity in short-term diabetic rats. Eur Pharmacol 2001; 431: 71-79. Cerca con Google

127. Pradhan A.D., Manson J.E., Rifai N. et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334. Cerca con Google

128. Radomski M.W., Palmer R.M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-646. Cerca con Google

129. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol. 2004;18:2854-65 Cerca con Google

130. Revankar CM., Cimino DF., Sklar LA. et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307:1625-1630 Cerca con Google

131. Rogatsky I., Trowbridge JM. And Garabedian MJ. Potentation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by cyclin A-CDK2 complex. J Biol Chem 1999; 274: 22296-22302 Cerca con Google

132. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibres. J Cell Biol 1971; 50: 172-186. Cerca con Google

133. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, Couse JF, Curtis SW, Korach KS. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta - gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997;99:2429-2437. Cerca con Google

134. Sack M.N., Rader D.I., Cannon R.O.III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269-270. Cerca con Google

135. Schaffer SW., Mozaffari MS., Artman M., Wilson GL. Basis for myocardial mechanical defects associated with non-insulin-dependent diabetes. Am J Physiol. 1989;256:E25-30 Cerca con Google

136. Schreihofer DA., Stoler MH., Shupnik MA. Differential expression and regulation of estrogen receptors (ERs) in rat pituitary and cell lines: estrogen decreases ER? protein and estrogen responsiveness. Endocrinology. 2000;141:2174-2184. Cerca con Google

137. Shanker G., Sorci-Thomas M., Adams M.R. Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells. Lymphok Cytok Res 1994; 13:377-382. Cerca con Google

138. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 2002;105:1368-73. Cerca con Google

139. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-41. Cerca con Google

140. Srivastava S., Weitzmann M.N., Cenci S. et al. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-jun and junD. J Clin Invest 1999; 104: 503-513. Cerca con Google

141. Staufer SR., Coletta CJ., Tedesco R. et al. Pyrazole ligands: structure-affinity/activity relationship and estrogen receptor--selective agonists. J Med Chem 2000; 43:4934-4947 Cerca con Google

142. Sun J., Huang Y.R., Harrington W.R. et al. Antagonists selective for estrogen receptor . Endocrinology 2002; 143: 941-947. Cerca con Google

143. Suzuki A., Mizuno K. InoY. et al. Effects of 17 beta-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro. Cardiovasc Res 1996; 32: 516-523. Cerca con Google

144. Tager H. Abnormal products of the human insulin gene. Diabetes 1984; 33: 693-699. Cerca con Google

145. Tamir S., Izrael S.,Vaya J. The effect of oxidative stress on ER? and ER? expression. J Steroid Biochem Mol Biol, 2002; 81: 327-33. Cerca con Google

146. Tiidus P.M. Radical species in inflammation and overtraining. Can J Physiol Pharmacol 1998; 76: 533-538. Cerca con Google

147. Tomlinson K, Gardiner SM, Bennett T. Diabetes mellitus in Brattleboro rats: cardiovascular, fluid, and electrolyte status. Am J Physiol 1989; 256: R1279-R1285. Cerca con Google

148. Tomlinson K.C., Gardiner S.M., Hebden RA et al. Functional consequences of streptozotocin-induced diabetes mellitus, with particolar reference to the cardiovascular system. Pharmacol Rev 1992; 44: 103-150 Cerca con Google

149. Tsao P.S., Wang B., Buitrago R. et al. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96: 934-940. Cerca con Google

150. Vegeto E, Pollio G, Pellicciari C, Maggi A. Estrogen and progesterone induction of survival of monoblastoid cells undergoing TNF-alpha-induced apoptosis. FASEB J. 1999;13:793- 803. Cerca con Google

151. Vegeto E., Belcredito S., Etteri S., et al Estrogen receptor-alpha mediates the antiinflammatory activity of estradiol. Proc Natl Acad Sci USA 2003; 100:9614-9619 Cerca con Google

152. Wade CB., Robinson S., Shapiro RA., Dorsa DM., Estrogen receptor ERalpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 2001; 142: 2336-2342 Cerca con Google

153. Ward JD. Diabetic neuropathy. Br Med Bull 1989; 45:111-126 Cerca con Google

154. Watters JJ. Dorsa DM., Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms J Neurosci 1998; 18: 6672-6680 Cerca con Google

155. Wellman G.C., Bonev A.D., Nelson M.T. et al. Gender differences in coronary artery diameter involve estrogen, nitric oxide and Ca2+ dependent K+ channels. Circ Res 1996; 79: 1024-1030. Cerca con Google

156. Wilcox JG., Hwang J., Hodis HN. et al. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistence and oxidation of low-density lipoprotein. Fertil Steril 1997; 67: 57-62 Cerca con Google

157. Zancan V., Santagati S., Bolego C. et al. 17?-estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells. Endocrinology 1999; 140: 2004-2009. Cerca con Google

158. Zhang Y., Lee FY., Barrera G., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006-1011. Cerca con Google

159. Zhu Y., Bian Z., Lu P. et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor ?. Science. 2002;295:505-508. Cerca con Google

160. Zwijsen RM., Wientjens E., Klompmaker R. et al. CDK-indipendent activation of estrogen receptor by ciclin D. Cell 1997; 88:405-415 Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record